AMLX - Amylyx Pharmaceuticals, Inc.

17.57
-0.790   -4.496%

Share volume: 763,975
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$18.36
-0.79
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 20%
Liquidity 58%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.90%
1 Month
29.86%
3 Months
3.84%
6 Months
14.91%
1 Year
315.37%
2 Year
787.37%
Key data
Stock price
$17.57
P/E Ratio 
N/A
DAY RANGE
$17.50 - $18.20
EPS 
-$1.61
52 WEEK RANGE
$4.20 - $18.60
52 WEEK CHANGE
$257.11
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
110.537 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
2.80
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,242,159
AVERAGE 30 VOLUME 
$1,265,543
Company detail
CEO: Joshua B. Cohen
Region: US
Website: amylyx.com
Employees: 200
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Amylyx Pharmaceuticals, Inc. develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid.

Recent news